Summit Therapeutics (SMMT) Enterprise Value (2018 - 2025)
Summit Therapeutics (SMMT) has disclosed Enterprise Value for 7 consecutive years, with -$238.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value fell 153.52% year-over-year to -$238.6 million, compared with a TTM value of -$172.9 million through Dec 2025, up 58.07%, and an annual FY2024 reading of -$412.3 million, down 477.32% over the prior year.
- Enterprise Value was -$238.6 million for Q3 2025 at Summit Therapeutics, up from -$297.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$23.8 million in Q3 2023 and bottomed at -$648.6 million in Q4 2022.
- Average Enterprise Value over 5 years is -$183.2 million, with a median of -$102.2 million recorded in 2021.
- The sharpest move saw Enterprise Value surged 88.99% in 2023, then plummeted 935.93% in 2025.
- Year by year, Enterprise Value stood at -$71.8 million in 2021, then tumbled by 803.47% to -$648.6 million in 2022, then soared by 88.99% to -$71.4 million in 2023, then plummeted by 477.32% to -$412.3 million in 2024, then skyrocketed by 42.15% to -$238.6 million in 2025.
- Business Quant data shows Enterprise Value for SMMT at -$238.6 million in Q3 2025, -$297.9 million in Q2 2025, and -$361.3 million in Q1 2025.